In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $9.69.
Wang covers the Healthcare sector, focusing on stocks such as Legend Biotech, Vertex Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Wang has an average return of 9.3% and a 46.19% success rate on recommended stocks.
Solid Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $20.83.
Based on Solid Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $20.98 million. In comparison, last year the company had a GAAP net loss of $20.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Solid Biosciences (SLDB) Company Description:
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
Read More on SLDB:
- Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
- Solid Biosciences receives Rae Pediatric Disease designation for SGT-003
- Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
